

BACKGROUND:

Despite being available for over 45 years, long-acting injectable (LAI) antipsychotics remain an underutilized treatment option for people with serious and persistent mental illness.

TARGET POPULATION AND OUTCOMES:

Used primarily for individuals who struggle with adherence to antipsychotic medication, these medications have been demonstrated through research to help:

- ▶ Improve adherence
- ▶ Reduce the frequency of symptom relapse
- ▶ Reduce re-hospitalization
- ▶ Improve treatment outcomes

TOOL KIT:

This toolkit provides information and resources pertaining to long acting injectables (LAIs). The purpose of the toolkit is to support your efforts to provide a seamless transition for your patients from the inpatient setting to the community.

LAI toolkit includes:

- ▶ Physical Health Plans LAI Formulary Grid
- ▶ Prior Authorization Forms*
- ▶ List of CBH in-network CIRC and Outpatient providers that administer LAIs
- ▶ LAI Referral and Resource Process Flow
- ▶ Information about care coordination services offered by pharmaceutical companies (below)

*Each Physical Health Plan in the region has a unique formulary and as such the long-acting injectables (LAIs) on formulary differ slightly amongst plans. The toolkit includes *Prior Authorization Forms* unique to each plan.

CARE COORDINATION WITH PHARMACEUTICAL COMPANIES:

Certain pharmaceutical companies offer care coordination services; these companies are listed below, with links for further information:

- ▶ [Aristada Patient Assistance](#)
- ▶ [Abilify Maintena Patient Assistance](#)
- ▶ [Invega Sustenna Patient Assistance](#)
- ▶ [Risperdal Consta Patient Assistance](#)
- ▶ [Zyprexa Relprevv Patient Assistance](#)
- ▶ [Invega Trinza Patient Assistance](#)
- ▶ [Haldol Decanoate Patient Assistance](#)

CURRENT FDA-APPROVED LAI MEDICATIONS:

- ▶ Haldol Decanoate
- ▶ Aristada
- ▶ Aristada Initio
- ▶ Risperdal Consta
- ▶ Invega Sustenna
- ▶ Invega Trinza
- ▶ Abilify Maintena
- ▶ Zyprexa Relprevv